Literature DB >> 26405313

Ledipasvir/Sofosbuvir.

Dennis J Cada1, Danial E Baker2, Ross Jason Bindler3.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The March 2015 monograph topics are paritaprevir, ritonavir, ombitasvir, and dasabuvir; meningococcal B bivalent recombinant vaccine; alemtuzumab; ceftolozane/tazobactam; and peramivir solution. The Safety MUE is on peramivir solution.

Entities:  

Year:  2015        PMID： 26405313      PMCID： PMC4567193          DOI： 10.1310/hpj5003-224

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  14 in total

1.  Hepatitis C in the United States.

Authors:  Scott D Holmberg; Philip R Spradling; Anne C Moorman; Maxine M Denniston
Journal:  N Engl J Med       Date:  2013-05-16       Impact factor: 91.245

2.  Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects.

Authors:  P German; L Moorehead; Phillip Pang; M Vimal; A Mathias
Journal:  J Clin Pharmacol       Date:  2014-06-24       Impact factor: 3.126

3.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Authors:  Nezam Afdhal; Stefan Zeuzem; Paul Kwo; Mario Chojkier; Norman Gitlin; Massimo Puoti; Manuel Romero-Gomez; Jean-Pierre Zarski; Kosh Agarwal; Peter Buggisch; Graham R Foster; Norbert Bräu; Maria Buti; Ira M Jacobson; G Mani Subramanian; Xiao Ding; Hongmei Mo; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Alessandra Mangia; Patrick Marcellin
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

4.  A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.

Authors:  Eric J Lawitz; Daniel Gruener; John M Hill; Thomas Marbury; Lisa Moorehead; Anita Mathias; Guofeng Cheng; John O Link; Kelly A Wong; Hongmei Mo; John G McHutchison; Diana M Brainard
Journal:  J Hepatol       Date:  2012-02-05       Impact factor: 25.083

5.  Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

Authors:  Eric Lawitz; Fred F Poordad; Phillip S Pang; Robert H Hyland; Xiao Ding; Hongmei Mo; William T Symonds; John G McHutchison; Fernando E Membreno
Journal:  Lancet       Date:  2013-11-05       Impact factor: 79.321

6.  Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection.

Authors:  John O Link; James G Taylor; Lianhong Xu; Michael Mitchell; Hongyan Guo; Hongtao Liu; Darryl Kato; Thorsten Kirschberg; Jianyu Sun; Neil Squires; Jay Parrish; Terry Kellar; Zheng-Yu Yang; Chris Yang; Mike Matles; Yujin Wang; Kelly Wang; Guofeng Cheng; Yang Tian; Erik Mogalian; Elsa Mondou; Melanie Cornpropst; Jason Perry; Manoj C Desai
Journal:  J Med Chem       Date:  2014-01-10       Impact factor: 7.446

7.  Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.

Authors:  Edward J Gane; Catherine A Stedman; Robert H Hyland; Xiao Ding; Evguenia Svarovskaia; G Mani Subramanian; William T Symonds; John G McHutchison; Phillip S Pang
Journal:  Gastroenterology       Date:  2013-11-18       Impact factor: 22.682

8.  Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885.

Authors:  Kelly A Wong; Angela Worth; Ross Martin; Evguenia Svarovskaia; Diana M Brainard; Eric Lawitz; Michael D Miller; Hongmei Mo
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

9.  Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors.

Authors:  Dennis Hernandez; Nannan Zhou; Joseph Ueland; Aaron Monikowski; Fiona McPhee
Journal:  J Clin Virol       Date:  2013-02-04       Impact factor: 3.168

10.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Authors:  Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245
View more
  2 in total

1.  Drug Interchangeability of Generic and Brand Products of Fixed Dose Combination Tablets of Sofosbuvir and Ledipasvir (400/90 mg): Employment of Reference Scaled Average Bioequivalence Study on Healthy Egyptian Volunteers.

Authors:  Ehab Rasmy Bendas; Mamdouh R Rezk; Kamal A Badr
Journal:  Clin Drug Investig       Date:  2018-05       Impact factor: 2.859

2.  Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial.

Authors:  Mohamed Abdel-Salam Elgohary; Eman Medhat Hasan; Amany Ahmad Ibrahim; Mohamed Farouk Ahmed Abdelsalam; Raafat Zaher Abdel-Rahman; Ashraf Ibrahim Zaki; Mohamed Bakr Elaatar; Mohamed Thabet Elnagar; Mohamed Emam Emam; Mahmoud Moustafa Hamada; Taimour Mohamed Abdel-Hamid; Ahmad Samir Abdel-Hafez; Mohamed Gomaa Seadawy; Ahmad Rashad Fatoh; Mohamed Ali Elsaied; Marwa Abdel-Rahman Sakr; Ahmed Omar Elkady; Mohamed Muawad Shehata; Osama Mohamed Nawar; Mohamed Abu-Elnaga Selem; Mohamed Saeed Abd-Aal; Hany Hafez Lotfy; Tarek Refaat Elnagdy; Sherine Helmy; Magdy Amin Mubark
Journal:  J Med Life       Date:  2022-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.